Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics

1 minute, 56 seconds Read

Bio-Techni Corporation today announced that Advanced Cell Diagnostics (ACD), a Bio-Techni Spatial Biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.

Optimized for same-slide detection of protein and RNA biomarkers with unmatched sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with manual and automated assays. Bio-Tech’s recently announced best-in-class multiomics application on Lunaphor’s COMET platform incorporates ACD’s novel protease-free RNAscope workflow.

Simultaneous imaging of both RNA and protein biomarkers in the same tissue section will provide an unprecedented single-cell view of disease pathology and therapeutic response. The new innovation in ACD marks a significant improvement over existing spatial technologies that are designed to detect either RNA or protein, not both, and typically lead to the degradation of alternative biomarker types.

Eliminating the need for proteases often used in RNA detection, this improved workflow preserves protein and RNA integrity and preserves tissue morphology. With these advances, subcellular gene expression and multiomic changes can be easily quantified, and image and data analysis are further simplified.

We are proud to have achieved another milestone in our spatial multimix strategy with the development of a novel, protease-free RNAscope workflow.. We have been impressed by the overwhelmingly positive feedback we have received from customers testing this new workflow with our current on-market RNAscope assays, and we look forward to offering this new capability across our RNAscope portfolio this year.

Kim Kelderman, Chief Operating Officer, Bio-Techni

Bio-Techne’s ACD brand is a pioneer in spatial biology, offering industry-leading single-molecule sensitivity and unmatched specificity with RNAscope ISH technology patented for over 10 years. With more than 9,500 peer-reviewed publications and more than 50,000 unique probes sold, RNAscope technology has enabled the spatial detection of a wide range of RNA subtypes in industry, from research to clinical applications.

The data will be presented in several activities at the Lunaphor Suite, Curacao 4, at the Advances in Genome Biology and Technology (AGBT) 2024 general meeting in Orlando, Florida, February 5-8. Additional data demonstrating technological advances in the coding of RNA with both protein and protein-protein interactions using RNAScope were presented at AGBT by ACD scientist Ge-Ah Kim, Ph.D. On February 7 poster #633 titled “Single-Slide, located in the usual place “Multiomic imaging of mRNA, protein, and protein-protein interactions in the tumor-immune microenvironment of bladder cancer patients.”

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *